Pharmaceutical Product Development Inc Company Profile and SWOT Analysis

Document Sample
Pharmaceutical Product Development Inc Company Profile and SWOT Analysis Powered By Docstoc
					Pharmaceutical Product Development, Inc.

_________________________________________________________________________________



Pharmaceutical Product                                                        Financial Snapshot

Development, Inc.                                                             Operating Performance

Fast Facts                                                                    The company reported revenues of US$1,470.57
                                                                              million during 2010, with a CAGR of 4.56% during
                                                                              2006–2010. Its revenue grew at an annual rate of
Headquarters Address              929 North Front Street, Wilmington, 28401
                                                                              3.80% over the previous fiscal year. In 2010, the
                                                                              company recorded an operating margin of 12.41%, as
Telephone                         + 1 910 2510081
                                                                              against 14.98% in 2009.
Fax                               + 1 910 5587056
                                                                              Revenue and Margins
Website                           www.ppdi.com

Ticker Symbol, Stock Exchange     PPDI, NASDAQ

Number of Employees               11,000

Fiscal Year End                   December

Revenue (in US$ million)          1,470.57




SWOT Analysis                                                                 Return on Equity

Strengths                         Weaknesses                                  The company recorded a return on equity (ROE) of
                                                                              9.69% for 2010, as compared to its peers, Covance
Aggressive acquisition strategy   Increasing operating expenses               Inc. (Ticker: CVD), Kendle International Inc. (Ticker:
                                                                              KNDL) and Omnicare, Inc. (Ticker: OCR), which
                                                                              recorded ROEs of 5.33%, -1.97% and -2.78%
Global presence                   Lawsuits                                    respectively. The company reported an operating
                                                                              margin of 12.41% in 2010.
Partnerships and alliances
                                                                              Return on Equity
Opportunities                     Threats

Contract with the US Army         Changing regulatory environments

Growing CRO industry              Foreign exchange risk

Service launches                  Uncertain R&D outcomes




                                                                              Liquidity Position

                                                                              The company reported a current ratio of 1.85 in 2010,
                                                                              as compared to its peers, Covance Inc., Kendle
                                                                              International Inc. and Omnicare, Inc., which recorded
                                                                              current ratios of 1.89, 1.36 and 4.13 respectively. As
                                                                              of December 2010, the company recorded cash and
                                                                              short-term investments of worth US$559.55 million,
                                                                              against zero current debt. The company reported a
                                                                              debt to equity ratio of 0.00 in 2010 as compared to its
                                                                              peers, Covance Inc., Kendle International Inc. and
                                                                              Omnicare, Inc., which recorded debt to equity ratios of
                                                                              0.10, 0.58 and 0.55 respectively.




___________________________________________________________________________________________

Pharmaceutical Product Development, Inc. - SWOT Profile                                                               Page 1
Pharmaceutical Product Development, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................7
    1.4       Key Financial Performance Indicators ...................................................................................................................9
      1.4.1       Revenue and Operating Profit ...........................................................................................................................9
      1.4.2       Asset, Liabilities and Capex .............................................................................................................................10
      1.4.3       Solvency ..........................................................................................................................................................11
      1.4.4       Valuation ..........................................................................................................................................................12
    1.5       Competitive Benchmarking ..................................................................................................................................13
      1.5.1       Market Capitalization .......................................................................................................................................13
      1.5.2       Efficiency ..........................................................................................................................................................14
      1.5.3       Capital Expenditure ..........................................................................................................................................15
      1.5.4       Turnover – Inventory and Asset.......................................................................................................................16
2     Mergers & Acquisitions and Partnerships ........................................................................................... 17
    2.1       M&A and Partnerships Strategy ...........................................................................................................................17
3     Recent Developments ........................................................................................................................... 21
4     SWOT Analysis ...................................................................................................................................... 23
    4.1       SWOT Analysis - Overview ..................................................................................................................................23
    4.2       Strengths ..............................................................................................................................................................23
    4.3       Weaknesses .........................................................................................................................................................24
    4.4       Opportunities ........................................................................................................................................................24
    4.5       Threats .........................................................................................................
				
DOCUMENT INFO
Description: This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business. ICD Research's "Pharmaceutical Product Development, Inc.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
BUY THIS DOCUMENT NOW PRICE: $99 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.